Zhong: Efficacy and safety of chloroquine for treatment of COVID-19. An open-label, multi-center, non-randomized trial [HCQ]

Efficacy and safety of chloroquine for treatment of COVID-19. An open-label, multi-center, non-randomized trial

Zhong Nanshan (钟南山) (Preprint)

Zhong, Efficacy and safety of chloroquine for treatment of COVID-19. An open-label, multi-center, non-randomized.., Nanshan (钟南山) (Preprint)

Mar 2020 Source PDF

Twitter
Facebook

All Studies Meta

197 patients. CQ effective. Day 10 viral RNA negative 91.4% HCQ versus 57.4% control. Median time to negative test 3 days versus 9 days for control.

Important missing comments or errors? Let us know.

risk of no virological cure at day 10, 80.0% lower, RR 0.20, p < 0.001, treatment 5 of 115 (4.3%), control 17 of 82 (20.7%), NNT 6.1, adjusted per study.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Zhong et al., 26 Mar 2020, retrospective, China, preprint, 1 author.

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit